Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia

NCT01324128 is registered in ClinicalTrials.gov with Vifor Pharma as lead sponsor.

NCT NCT01324128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01324128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomised, Active-controlled, Parallel Group, Multicentre, Phase 3 Study to Investigate the Safety and Efficacy of PA21 Compared With Sevelamer Carbonate Followed by a Randomised Comparison of PA21 Maintenance Dose Versus PA21-Low Dose in Dialysis Patients With Hyperphosphataemia
Lead sponsor
Vifor Pharma
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2011
Completion date
October 31, 2012
Enrollment
1,059 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease requiring chronic dialysis